Should This News Scare Amarin Investors?
Amarin investors rejoiced this summer after the company's drug, Vascepa, which is derived from a fish oil compound, was approved by the FDA. As a result, Amarin's share price has nearly doubled in value since the start of 2012, and the company is poised to market the drug in early 2013. Vascepa will compete with GlaxoSmithKline's triglyceride-lowering therapeutic Lovaza, which generated more than $900 million in sales for fiscal 2011.
However, recent studies challenge the notion that fish oil has positive benefits for the cardiovascular system. Does this news put Amarin's future drug sales in jeopardy? Healthcare bureau chief Brenton Flynn, and analyst Max Macaluso, discuss the news in the video below.
Amarin has had a great run so far this year, but it didn't make our list of the three Middle-Class Millionaire-Makers that Wall Street's too rich to notice. These stocks might be ignored by the 1%, but they could boost the returns in your portfolio -- just click here to read it now.
The article Should This News Scare Amarin Investors? originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.